知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

12 records (took 0.02 seconds)

    DIAGNOSTIC AND THERAPEUTIC METHODS FOR KIDNEY CANCER
    4.
    发明申请
    DIAGNOSTIC AND THERAPEUTIC METHODS FOR KIDNEY CANCER 有权

    公开(公告)号：US20210253710A1

    公开(公告)日：2021-08-19

    申请号：US17232263

    申请日：2021-04-16

    Applicant: Genentech, Inc.

    Inventor： Christina SCHIFF ,  Marjorie GREEN ,  Mahrukh HUSENI

    IPC: C07K16/28 ,  C07K16/22 ,  A61K45/06 ,  G01N33/574 ,  A61P35/00

    Abstract: The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of cancer (e.g., kidney cancer (e.g., renal cell carcinoma (RCC)). The invention is based, at least in part, on the discovery that expression levels of one or more biomarkers described herein in a sample from an individual having cancer can be used in methods of predicting the therapeutic efficacy of treatment with a VEGF antagonist (e.g., an anti-VEGF antibody, (e.g., bevacizumab) or a VEGFR inhibitor (e.g., a multi-targeted tyrosine kinase inhibitor (e.g., sunitinib, axitinib, pazopanib, or cabozantinib))) and a PD-L1 axis binding antagonist (e.g., a PD-L1 binding antagonist (e.g., anti-PD-L1 antibody, e.g., atezolizumab (MPDL3280A)) or a PD-1 binding antagonist (e.g., anti-PD-1 antibody)), or with an angiogenesis inhibitor (e.g., a VEGF antagonist (e.g., a VEGFR inhibitor, (e.g., a multi-targeted tyrosine kinase inhibitor (e.g., sunitinib, axitinib, pazopanib, or cabozantinib)))).

    DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER
    6.
    发明申请
    DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER 审中-公开

    公开(公告)号：US20200157635A1

    公开(公告)日：2020-05-21

    申请号：US16591813

    申请日：2019-10-03

    Applicant: Genentech, Inc.

    Inventor： Marcin KOWANETZ ,  Mahrukh HUSENI ,  Wei ZOU

    IPC: C12Q1/6886 ,  G01N33/50 ,  C07K16/28

    Abstract: The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of cancer. The invention is based, at least in part, on the discovery that an immune-score expression level based on one or more of PD-L1, CXCL9, IFNG, GZMB, CD8A, and PD-1 in a sample obtained from an individual having cancer can be used in methods of predicting the therapeutic efficacy of treatment with a PD-L1 axis binding antagonist (e.g., a PD-L1 binding antagonist (e.g., anti-PD-L1 antibody, e.g., atezolizumab (MPDL3280A)) or a PD-1 binding antagonist (e.g., anti-PD-1 antibody)).

    METHODS AND BIOMARKERS FOR PREDICTING EFFICACY AND EVALUATION OF AN OX40 AGONIST TREATMENT
    8.
    发明申请
    METHODS AND BIOMARKERS FOR PREDICTING EFFICACY AND EVALUATION OF AN OX40 AGONIST TREATMENT 审中-公开
    用于预测OX40激动剂治疗的有效性和评价的方法和生物标志物

    公开(公告)号：US20160160290A1

    公开(公告)日：2016-06-09

    申请号：US14930597

    申请日：2015-11-02

    Applicant: GENENTECH, INC.

    Inventor： Mahrukh HUSENI

    IPC: C12Q1/68 ,  C07K16/28

    CPC classification number: C12Q1/6886 ,  C07K16/2878 ,  C07K2317/24 ,  C07K2317/75 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/57484 ,  G01N2800/52

    Abstract: The present disclosure provides methods for predicting responsiveness of a subject having cancer to an OX40 agonist treatment by measuring the expression level of one or more biomarkers. Also provided are methods for monitoring pharmacodynamic activity of or responsiveness to an OX40 agonist treatment by measuring the expression level of one or more biomarkers. Further provided are methods related thereto for treating or delaying progression of cancer in a subject by administering an effective amount of an OX40 agonist to a subject. Specific biomarkers for all such methods are described herein.

    Abstract translation: 本公开提供了通过测量一种或多种生物标志物的表达水平来预测具有癌症的受试者对OX40激动剂治疗的反应性的方法。 还提供了通过测量一种或多种生物标志物的表达水平监测OX40激动剂治疗的药效学活性或对其的反应性的方法。 还提供了通过向受试者施用有效量的OX40激动剂来治疗或延缓受试者的癌症进展的方法。 所有这些方法的具体生物标志物在本文中描述。

    THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER
    9.
    发明公开
    THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER 审中-公开

    公开(公告)号：US20240060135A1

    公开(公告)日：2024-02-22

    申请号：US17937102

    申请日：2022-09-30

    Applicant: Genentech, Inc.

    Inventor： Li-Fen LIU ,  Sanjeev MARIATHASAN ,  Chi Yung YUEN ,  Mahrukh HUSENI

    IPC: C12Q1/6886 ,  A61P35/00 ,  C07K16/28 ,  G01N33/574

    CPC classification number: C12Q1/6886 ,  A61P35/00 ,  C07K16/2827 ,  G01N33/57484 ,  C07K2317/24 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N2333/5421

    Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer (e.g., bladder cancer (e.g., UC) or kidney cancer (e.g., RCC)). The invention provides methods of identifying an individual having a cancer who is likely to respond to treatment with an anti-cancer therapy comprising a PD-L1 axis binding antagonist, methods for selecting a therapy for an individual having a cancer, methods of identifying an individual having a cancer who is less likely to respond to treatment with an anti-cancer therapy comprising a PD-L1 axis binding antagonist monotherapy, methods of monitoring the response of an individual having a cancer to treatment with an anti-cancer therapy comprising a PD-L1 axis binding antagonist, and methods of treating an individual having cancer, based on expression levels of a biomarker of the invention (e.g., one or more genes set forth in any one of Tables 1-7, e.g., IL8).

    DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER
    10.
    发明申请
    DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER 有权

    公开(公告)号：US20230082122A1

    公开(公告)日：2023-03-16

    申请号：US17835418

    申请日：2022-06-08

    Applicant: Genentech, Inc.

    Inventor： Priti HEGDE ,  Mahrukh HUSENI

    IPC: G01N33/574 ,  A61P35/04 ,  A61K31/404 ,  A61K39/395 ,  A61K45/06 ,  C07K16/22 ,  C07K16/28 ,  C12Q1/6886

    Abstract: The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of cancer (e.g., kidney cancer (e.g., renal cell carcinoma (RCC)), lung cancer (e.g., non-small cell lung cancer (NSCLC)), bladder cancer (e.g., urothelial bladder cancer (UBC)), liver cancer (e.g., hepatocellular carcinoma (HCC)), ovarian cancer, or breast cancer (e.g., triple-negative breast cancer (TNBC))). The invention is based, at least in part, on the discovery that expression levels of one or more biomarkers described herein in a sample from an individual having cancer can be used in methods of predicting the therapeutic efficacy of treatment with a VEGF antagonist (e.g., an anti-VEGF antibody, (e.g., bevacizumab) or a VEGFR inhibitor (e.g., a multi-targeted tyrosine kinase inhibitor (e.g., sunitinib, axitinib, pazopanib, or cabozantinib))) and a PD-L1 axis binding antagonist (e.g., a PD-L1 binding antagonist (e.g., anti-PD-L1 antibody, e.g., atezolizumab (MPDL3280A)) or a PD-1 binding antagonist (e.g., anti-PD-1 antibody)), or with an angiogenesis inhibitor (e.g., a VEGF antagonist (e.g., a VEGFR inhibitor, (e.g., a multi-targeted tyrosine kinase inhibitor (e.g., sunitinib, axitinib, pazopanib, or cabozantinib)))).

Patent Agency Ranking